These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 35098659)
1. Baseline data of a sequential multiple assignment randomized trial (STEP study). Hartmann JA; Nelson B; Amminger GP; Spark J; Yuen HP; Kerr MJ; Polari A; Wallis N; Blasioli J; Dixon L; Carter C; Loewy R; Niendam TA; Shumway M; McGorry PD Early Interv Psychiatry; 2022 Oct; 16(10):1130-1142. PubMed ID: 35098659 [TBL] [Abstract][Full Text] [Related]
2. A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized Trial. McGorry PD; Mei C; Amminger GP; Yuen HP; Kerr M; Spark J; Wallis N; Polari A; Baird S; Buccilli K; Dempsey SA; Ferguson N; Formica M; Krcmar M; Quinn AL; Mebrahtu Y; Ruslins A; Street R; Wannan C; Dixon L; Carter C; Loewy R; Niendam TA; Shumway M; Nelson B JAMA Psychiatry; 2023 Sep; 80(9):875-885. PubMed ID: 37378974 [TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
4. Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Nelson B; Amminger GP; Yuen HP; Wallis N; J Kerr M; Dixon L; Carter C; Loewy R; Niendam TA; Shumway M; Morris S; Blasioli J; McGorry PD Early Interv Psychiatry; 2018 Jun; 12(3):292-306. PubMed ID: 28719151 [TBL] [Abstract][Full Text] [Related]
5. Early psychotic experiences: Interventions, problems and perspectives. Dimitrakopoulos S; Kollias C; Stefanis NC; Kontaxakis V Psychiatriki; 2015; 26(1):45-54. PubMed ID: 25880383 [TBL] [Abstract][Full Text] [Related]
6. Staged treatment and acceptability guidelines in early psychosis study (STAGES): A randomized placebo controlled trial of intensive psychosocial treatment plus or minus antipsychotic medication for first-episode psychosis with low-risk of self-harm or aggression. Study protocol and baseline characteristics of participants. O'Donoghue B; Francey SM; Nelson B; Ratheesh A; Allott K; Graham J; Baldwin L; Alvarez-Jimenez M; Thompson A; Fornito A; Polari A; Berk M; Macneil C; Crisp K; Pantelis C; Yuen HP; Harrigan S; McGorry P Early Interv Psychiatry; 2019 Aug; 13(4):953-960. PubMed ID: 30024100 [TBL] [Abstract][Full Text] [Related]
7. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study. Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A; Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925 [TBL] [Abstract][Full Text] [Related]
8. Prescription of antipsychotic medication to patients at ultra high risk of developing psychosis. Nieman DH; Rike WH; Becker HE; Dingemans PM; van Amelsvoort TA; de Haan L; van der Gaag M; Denys DA; Linszen DH Int Clin Psychopharmacol; 2009 Jul; 24(4):223-8. PubMed ID: 19521246 [TBL] [Abstract][Full Text] [Related]
9. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114 [TBL] [Abstract][Full Text] [Related]
10. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978 [TBL] [Abstract][Full Text] [Related]
11. NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. Markulev C; McGorry PD; Nelson B; Yuen HP; Schaefer M; Yung AR; Thompson A; Berger G; Mossaheb N; Schlögelhofer M; Smesny S; de Haan L; Riecher-Rössler A; Nordentoft M; Chen EYH; Verma S; Hickie I; Amminger GP Early Interv Psychiatry; 2017 Oct; 11(5):418-428. PubMed ID: 26279065 [TBL] [Abstract][Full Text] [Related]
12. The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Walker EF; Cornblatt BA; Addington J; Cadenhead KS; Cannon TD; McGlashan TH; Perkins DO; Seidman LJ; Tsuang MT; Woods SW; Heinssen R Schizophr Res; 2009 Nov; 115(1):50-7. PubMed ID: 19709859 [TBL] [Abstract][Full Text] [Related]
13. A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol. Qurashi I; Chaudhry IB; Khoso AB; Farooque S; Lane S; Husain MO; Chu S; Sarginson J; Hamarani M; Naqvi HA; Razzaque B; Minhas FA; Yung AR; Deakin JFW; Husain N Trials; 2017 Nov; 18(1):524. PubMed ID: 29121974 [TBL] [Abstract][Full Text] [Related]
14. Switching antipsychotic medication to reduce sexual dysfunction in people with psychosis: the REMEDY RCT. Crawford MJ; Thana L; Evans R; Carne A; O'Connell L; Claringbold A; Saravanamuthu A; Case R; Munjiza J; Jayacodi S; Reilly JG; Hughes E; Hoare Z; Barrett B; Leeson VC; Paton C; Keown P; Pappa S; Green C; Barnes TR Health Technol Assess; 2020 Sep; 24(44):1-54. PubMed ID: 32930090 [TBL] [Abstract][Full Text] [Related]
15. [Detection and early treatment of subjects at high risk of clinical psychosis: Definitions and recommendations]. Michel C; Toffel E; Schmidt SJ; Eliez S; Armando M; Solida-Tozzi A; Schultze-Lutter F; Debbané M Encephale; 2017 May; 43(3):292-297. PubMed ID: 28347521 [TBL] [Abstract][Full Text] [Related]
16. Predictors of remission from the ultra-high risk state for psychosis. Glenthøj LB; Kristensen TD; Wenneberg C; Hjorthøj C; Nordentoft M Early Interv Psychiatry; 2021 Feb; 15(1):104-112. PubMed ID: 31910496 [TBL] [Abstract][Full Text] [Related]
17. Rationale for clinical interventions in prodromal psychosis. Are such interventions safe? Agius M; Butler S Psychiatr Danub; 2012 Sep; 24 Suppl 1():S28-35. PubMed ID: 22945183 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. Lam M; Lee J; Rapisarda A; See YM; Yang Z; Lee SA; Abdul-Rashid NA; Kraus M; Subramaniam M; Chong SA; Keefe RSE JAMA Psychiatry; 2018 Sep; 75(9):929-939. PubMed ID: 30046827 [TBL] [Abstract][Full Text] [Related]
19. Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids. Amminger GP; Mechelli A; Rice S; Kim SW; Klier CM; McNamara RK; Berk M; McGorry PD; Schäfer MR Transl Psychiatry; 2015 Jan; 5(1):e495. PubMed ID: 25585167 [TBL] [Abstract][Full Text] [Related]
20. [Early detection of psychotic disorders]. Schäfer MR; Klier CM; Papageorgiou K; Friedrich MH; Amminger GP Neuropsychiatr; 2007; 21(1):37-44. PubMed ID: 17555006 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]